Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE and SBRT in Unresectable HCC
NCT02513199Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2014
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hepatocellular carcinoma (HCC), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Objective Response Rate at 72 months. Started Nov 2014; status: completed.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02513199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513199.